Expression and clinical value of LncRNA NNT-AS1 and MNX1-AS1 in lung cancer patients_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

BI Xin ¹ , GUO Juntang ² ,  ZHANG Zhimin ¹

1. Department of Chest Surgery, The Third Medical Center of The General Hospital of The People’s Liberation Army, Beijing 100039, P. R. China;
2. Department of Chest Surgery, The First Medical Center of The General Hospital of the People’s Liberation Army, Beijing 100853, P. R. China;

Corresponding?author：

ZHANG Zhimin, Email: 774022337@qq.com

Keywords：

Long chain non-coding RNA nicotinamide nucleotide hydrogenase antisense RNA1; motor neuron and pancreas homeobox protein 1 antisense RNA 1; lung cancer

DOI：

10.7507/1671-6205.202404053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression and clinical value of long chain non-coding RNA nicotinamide nucleotide hydrogenase antisense RNA1 (LncRNA NNT-AS1), motor neuron and pancreas homeobox protein 1 antisense RNA1 (MNX1-AS1) in lung cancer patients. Methods This study selected 128 patients diagnosed with lung cancer admitted to The Third Medical Center of the General Hospital of the People’s Liberation Army from April 2020 to April 2021 as a cancer group. During the same period, 128 patients with benign pulmonary nodules were regarded as a benign group, and 128 healthy individuals who underwent physical examination were selected as a control group. Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the levels of LncRNA NNT-AS1 and MNX1-AS1 in serum. A three-year follow-up was conducted on all lung cancer patients, with 52 patients in the death group and 76 patients in the survival group. Receiver operator characteristic (ROC) curve was applied to analyze the diagnostic value of serum LncRNA NNT-AS1 and MNX1-AS1 for the occurrence of lung cancer and their predictive value for prognosis. Results Compared with the control group, the serum levels of LncRNA NNT-AS1 and MNX1-AS1 were obviously increased in the benign group and the cancer group (P<0.05). Compared with the benign group, the levels of LncRNA NNT-AS1 and MNX1-AS1 in serum of the cancer patients were obviously increased (P<0.05). The area under ROC curve (AUC) of serum LncRNA NNT-AS1 combined with MNX1-AS1 for the diagnosis of lung cancer was higher than that of LncRNA NNT-AS1 and MNX1-AS1 alone (Z_{LncRNA NNT-AS1~LncRNA NNT-AS1+MNX1-AS1}=2.496, P=0.013; Z_{MNX1-AS1~LncRNA NNT-AS1+MNX1-AS1}=2.831, P=0.007). The levels of LncRNA NNT-AS1 and MNX1-AS1 were related to tumor differentiation, clinical stage, and lymph node metastasis (P<0.05). Compared with the survival group, the serum levels of LncRNA NNT-AS1 and MNX1-AS1 in the death group were obviously increased (P<0.05). The AUC of combined prediction for lung cancer prognosis by serum LncRNA NNT-AS1 and MNX1-AS1 was higher than that predicted by LncRNA NNT-AS1 and MNX1-AS1 alone (Z_{LncRNA NNT-AS1~LncRNA NNT-AS1+MNX1-AS1}=2.539, P=0.011; Z_{MNX1-AS1~LncRNA NNT-AS1+MNX1-AS1}=3.377, P=0.001). Conclusion LncRNA NNT-AS1 and MNX1-AS1 are highly expressed in serum of lung cancer patients, and both have certain value in diagnosis and prognosis evaluation of lung cancer.

Citation： BI Xin, GUO Juntang, ZHANG Zhimin. Expression and clinical value of LncRNA NNT-AS1 and MNX1-AS1 in lung cancer patients. Chinese Journal of Respiratory and Critical Care Medicine, 2025, 24(2): 86-91. doi: 10.7507/1671-6205.202404053 Copy

1.	胡博文, 杜玲玉, 楊勇. CTCs作為NSCLC診斷預后指標及在PD-1/PD-L1免疫治療中的研究回顧. 中文科技期刊數據庫(引文版)醫藥衛生, 2022, 6(2): 10-15.
2.	饒德新, 潘麗紅, 劉恒, 等. 血清miR-134-5p和趨化因子20對非小細胞肺癌患者肺癌根治術后復發轉移的預測價值. 中華實用診斷與治療雜志, 2022, 36(2): 130-135.
3.	趙齊林, 王楠, 李亞霽, 等. Lnc-TMEM132D-AS1高表達明顯降低非小細胞肺癌對奧希替尼的敏感性. 南方醫科大學學報, 2023, 43(2): 242-250.
4.	馬宇光, 昝瑛, 王夢, 等. LncRNA NNT-AS1和miR-424在子宮內膜癌組織中的表達及其臨床意義. 國際檢驗醫學雜志, 2021, 42(11): 1376-1381.
5.	Yang R, Wang L, Han M. MNX1-AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma. J Cell Biochem, 2019, 120(5): 7222-7228.
6.	中華醫學會, 中華醫學會腫瘤學分會, 中華醫學會雜志社. 中華醫學會肺癌臨床診療指南(2018版). 中華腫瘤雜志, 2018, 40(12): 935-964.
7.	羅巧, 石宏, 王紹波. α7-煙堿乙酰膽堿受體在肺癌發生, 發展及治療中的作用. 昆明醫科大學學報, 2022, 43(2): 145-149.
8.	趙曼, 祝德, 張洪洋. 巴中市非小細胞肺癌患者EGFR基因突變及環境暴露因素分析. 公共衛生與預防醫學, 2023, 34(4): 128-131.
9.	閆星, 劉山梅, 劉長宏. 不同體液標本活檢在肺癌微小殘留疾病監測中的應用最新進展. 中國全科醫學, 2023, 26(3): 280-286.
10.	趙娜, 丁寧, 朱蓉. 不同腫瘤分期肺癌合并下肢靜脈血栓患者的炎癥因子, 凝血及纖溶指標表達水平的差異及其與疾病的相關性分析. 臨床和實驗醫學雜志, 2023, 22(5): 457-461.
11.	賈剛剛, 李斌, 盧利霞, 等. 長鏈非編碼RNA-NEF在肝癌, 胃癌, 食管癌發生發展中的作用. 中國醫藥導報, 2023, 20(12): 52-55.
12.	劉尚, 郭莉媛. 長鏈非編碼RNA AFAP1-AS1在實體腫瘤中的作用與分子機制. 現代腫瘤醫學, 2020, 28(8): 1390-1394.
13.	郎海雷, 曹雷濤, 貴英斌, 等. LncRNANNT-AS1通過調控miR-582-5p/NCKAP1軸激活Hippo-YAP/TAZ信號通路促進膀胱癌細胞增殖, 遷移, 侵襲和干細胞干性影響. 現代檢驗醫學雜志, 2023, 38(4): 27-34.
14.	Hua F , Liu S , Zhu L , et al. Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancer. Biomed Pharmacother, 2017, 92: 1128-1134.
15.	劉高峰, 張勇, 張小貞, 等. LncRNA MNX-AS1在非小細胞肺癌組織中的表達及臨床意義. 河北醫學, 2021, 27(3): 486-490.
16.	葉暉. LncRNA NNT--AS1過表達與骨肉瘤進展及不良預后的相關性研究. 廣州: 南方醫科大學, 2023.
17.	Yin H, Hu J, Ye Z, et al. Serum long non-coding RNA NNT-AS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer. Mol Med Rep, 2021, 24(2): 585-597.
18.	Cai Y, Dong ZY, Wang JY. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci, 2018, 22(4): 4879-4887.
19.	Shuai Y, Ma Z, Liu W, et al. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. Mol Cancer, 2020, 19(1): 6-18.
20.	Liu G, Zhang Y, Zhang X, et al. LncRNA MNX1-AS1 contributes to lung adenocarcinoma progression by targeting the miR-34a/SIRT1 axis. Am J Transl Res, 2022, 14(7): 4977-4989.
21.	Shen Y, Lv M, Fang Y, et al. LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis. J Ovarian Res, 2021, 14(1): 161-179.
22.	Braga EA, Fridman MV, Burdennyy AM, et al. Various LncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci, 2023, 24(17): 13617-13625.

1. 胡博文, 杜玲玉, 楊勇. CTCs作為NSCLC診斷預后指標及在PD-1/PD-L1免疫治療中的研究回顧. 中文科技期刊數據庫(引文版)醫藥衛生, 2022, 6(2): 10-15.
2. 饒德新, 潘麗紅, 劉恒, 等. 血清miR-134-5p和趨化因子20對非小細胞肺癌患者肺癌根治術后復發轉移的預測價值. 中華實用診斷與治療雜志, 2022, 36(2): 130-135.
3. 趙齊林, 王楠, 李亞霽, 等. Lnc-TMEM132D-AS1高表達明顯降低非小細胞肺癌對奧希替尼的敏感性. 南方醫科大學學報, 2023, 43(2): 242-250.
4. 馬宇光, 昝瑛, 王夢, 等. LncRNA NNT-AS1和miR-424在子宮內膜癌組織中的表達及其臨床意義. 國際檢驗醫學雜志, 2021, 42(11): 1376-1381.
5. Yang R, Wang L, Han M. MNX1-AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma. J Cell Biochem, 2019, 120(5): 7222-7228.
6. 中華醫學會, 中華醫學會腫瘤學分會, 中華醫學會雜志社. 中華醫學會肺癌臨床診療指南(2018版). 中華腫瘤雜志, 2018, 40(12): 935-964.
7. 羅巧, 石宏, 王紹波. α7-煙堿乙酰膽堿受體在肺癌發生, 發展及治療中的作用. 昆明醫科大學學報, 2022, 43(2): 145-149.
8. 趙曼, 祝德, 張洪洋. 巴中市非小細胞肺癌患者EGFR基因突變及環境暴露因素分析. 公共衛生與預防醫學, 2023, 34(4): 128-131.
9. 閆星, 劉山梅, 劉長宏. 不同體液標本活檢在肺癌微小殘留疾病監測中的應用最新進展. 中國全科醫學, 2023, 26(3): 280-286.
10. 趙娜, 丁寧, 朱蓉. 不同腫瘤分期肺癌合并下肢靜脈血栓患者的炎癥因子, 凝血及纖溶指標表達水平的差異及其與疾病的相關性分析. 臨床和實驗醫學雜志, 2023, 22(5): 457-461.
11. 賈剛剛, 李斌, 盧利霞, 等. 長鏈非編碼RNA-NEF在肝癌, 胃癌, 食管癌發生發展中的作用. 中國醫藥導報, 2023, 20(12): 52-55.
12. 劉尚, 郭莉媛. 長鏈非編碼RNA AFAP1-AS1在實體腫瘤中的作用與分子機制. 現代腫瘤醫學, 2020, 28(8): 1390-1394.
13. 郎海雷, 曹雷濤, 貴英斌, 等. LncRNANNT-AS1通過調控miR-582-5p/NCKAP1軸激活Hippo-YAP/TAZ信號通路促進膀胱癌細胞增殖, 遷移, 侵襲和干細胞干性影響. 現代檢驗醫學雜志, 2023, 38(4): 27-34.
14. Hua F , Liu S , Zhu L , et al. Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancer. Biomed Pharmacother, 2017, 92: 1128-1134.
15. 劉高峰, 張勇, 張小貞, 等. LncRNA MNX-AS1在非小細胞肺癌組織中的表達及臨床意義. 河北醫學, 2021, 27(3): 486-490.
16. 葉暉. LncRNA NNT--AS1過表達與骨肉瘤進展及不良預后的相關性研究. 廣州: 南方醫科大學, 2023.
17. Yin H, Hu J, Ye Z, et al. Serum long non-coding RNA NNT-AS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer. Mol Med Rep, 2021, 24(2): 585-597.
18. Cai Y, Dong ZY, Wang JY. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci, 2018, 22(4): 4879-4887.
19. Shuai Y, Ma Z, Liu W, et al. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. Mol Cancer, 2020, 19(1): 6-18.
20. Liu G, Zhang Y, Zhang X, et al. LncRNA MNX1-AS1 contributes to lung adenocarcinoma progression by targeting the miR-34a/SIRT1 axis. Am J Transl Res, 2022, 14(7): 4977-4989.
21. Shen Y, Lv M, Fang Y, et al. LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis. J Ovarian Res, 2021, 14(1): 161-179.
22. Braga EA, Fridman MV, Burdennyy AM, et al. Various LncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci, 2023, 24(17): 13617-13625.

Chinese Journal of Respiratory and Critical Care Medicine

Expression and clinical value of LncRNA NNT-AS1 and MNX1-AS1 in lung cancer patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content